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Abstract  
Stroke is one of the leading causes of mortality and disability worldwide. Numerous 
pathophysiological mechanisms involving blood vessels, coagulation and inflammation 
contribute to the vascular occlusion. Perturbations in these pathways can be detected by 
numerous methods including changes in endoplasmic membrane remodeling and rearrangement 
leading to the shedding of microparticles (MPs) from various cellular origins in the blood. MPs 
are small membrane-derived vesicles that are shed from nearly all cells in the body in resting 
state or upon stimulation. MPs act as biological messengers to transfer information to adjacent 
and distant cells regulating thus various biological processes. MPs may be important biomarkers 
and tools for the identification of the risk and diagnosis of cerebrovascular diseases. Endothelial 
activation and dysfunction and altered thrombotic responses are two of the main features 
predisposing to stroke. Endothelial MPs (EMPs) have been recognized as both biomarkers and 
effectors of endothelial cell activation and injury while platelet-derived MPs (PMPs) carry a 
strong pro-coagulant potential and are activated in thrombotic states. Therefore, we reviewed 
here the role of EMPs and PMPs as biomarkers of stroke. Most studies reported high circulating 
levels of EMPs and PMPs in addition to other cell origins in stoke patients and have been linked 
to stroke severity, the size of infarction, and prognosis. The identification and quantification of 
EMPs and PMPs may thus be useful for the diagnosis and management of stroke. 
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Introduction 
Stroke is one of the most devastating neurological disorders and is considered one of the leading 
causes of long-term acquired disability in adults (Katan & Luft, 2018). It is considered to be the 
second main cause of mortality in the world after ischemic heart disease (IHD) (Benjamin et al., 
2018; Katan & Luft, 2018).  According to the American Heart Association (AHA) latest 
statistical update, there were 6.3 million deaths due to cerebrovascular diseases around the world 
(Benjamin et al., 2018). In addition, the direct and indirect cost of stroke is very high. In the 
USA (between 2013 and 2014), this cost was around $40.1 billion causing thus a major 
economic burden (Benjamin et al., 2018). Stroke is a very heterogeneous disease and includes 
several etiologies and subtypes (Amarenco, Bogousslavsky, Caplan, Donnan, & Hennerici, 
2009). Therefore, consistent definitions of clinical stroke and its subtypes is crucial for the 
proper interpretation of clinical trials and studies aiming to examine incidence, prevalence and 
mortality of stroke within predefined populations (Sacco et al., 2013). The World Health 
Organization (WHO) defined stroke in the 1970s as “rapidly developed clinical signs of focal (or 
global) disturbance of cerebral function, lasting more than 24 hours or leading to death, with no 
apparent cause other than of vascular origin” (Aho et al., 1980). However, since significant 
advances have been made in the clinical and radiographic diagnosis of stroke and its mimics, this 
definition is now considered outdated and does not reflect the heterogeneity and complexity of 
the disease. Consequently, in 2013, the AHA and the American Stroke Association (ASA) 
developed an expert consensus document for an updated definition of stroke, taking into account 
the remarkable advances in brain imaging and its clinical implications on the diagnosis of stroke 
and its subtypes (Coupland, Thapar, Qureshi, Jenkins, & Davies, 2017; Sacco et al., 2013). This 
document summarized different stroke etiologies and enlisted them in a table for a better 
definition of stroke. 
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Stroke can be classified into 2 major types; ischemic (~80 %) which is due to cerebral vessels’ 
blockade and hemorrhagic stroke (~20%) which is due to brain hemorrhage (Ojaghihaghighi, 
Vahdati, Mikaeilpour, & Ramouz, 2017). Each type is further classified into subtypes according 
to their etiology. Ischemic stroke has been classified according to Trial of ORG 10172 in Acute 
Stroke Treatment (TOAST) classification into 5 subtypes based on clinical features and other 
prognostic markers to; large artery atherosclerosis, small vessel occlusion, cardio-embolism, 
stroke of other determined etiology and stroke of undetermined etiology (Adams et al., 1993). 
Hemorrhagic stroke is divided into two subtypes based on bleeding location in the brain to; 
intracerebral hemorrhage (ICH) where bleeding is directly in brain parenchyma or subarachnoid 
hemorrhage (SAH) where bleeding takes place between arachnoid space and pia matter 
surrounding the brain (Ojaghihaghighi et al., 2017). However, other classifications are available 
for both types of stroke as well. 
There is no single outcome that can accurately measure and predict post-acute strokes disability 
and prognosis  (Kasner, 2006). Many scales have been developed to measure stroke outcomes 
including the modified Rankin scale (mRs), the National institutes of Health stroke scale 
(NIHSS), the Barthel index (BI), the stroke impact scale (SIS) and the Glasgow outcome scale 
(GOS) (Harrison, McArthur, & Quinn, 2013; Kasner, 2006). In addition, each scale has its 
advantages and pitfalls that must be taken into consideration before choosing a certain one 
(Kasner, 2006).  
Early and accurate stroke diagnosis is crucial in patient care in order to adopt the right 
therapeutic strategies and prevent permanent disabilities (Ojaghihaghighi et al., 2017). For 
instance, intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) which 
is currently the first line drug used for acute ischemic stroke treatment, is believed to be most 
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effective when administered within the first few hours of stroke onset (Gumbinger et al., 2014). 
Various clinical and radiographic tools are used to diagnose stroke (Sacco et al., 2013). Clinical 
manifestations and findings help clinicians to determine the type of stroke but usually brain 
imaging is required (Ojaghihaghighi et al., 2017). Computed tomography (CT) and magnetic 
resonance imaging (MRI) are used to recognize the brain lesion location, shape, size and extent 
and is helpful to determine the cause of stroke and exclude mimics (Sacco et al., 2013). Blood 
biomarkers, including S100 calcium binding protein, brain natriuretic peptides and matrix 
metalloproteinase-9 have also been evaluated in the diagnosis of acute stroke (Jickling & Sharp, 
2011; Sacco et al., 2013). However, these markers lack specificity since they are generated in 
other diseases that can also affect the blood brain barrier (BBB) (Kim, Moon, & Bang, 2013). 
Therefore, it is necessary to explore novel effective biomarkers to be used in the identification of 
high-risk patients, rapid diagnosis, determining stroke etiology and pathogenesis, predicting drug 
response and clinical outcomes, for novel drug development and as endpoints in clinical trials 
(Bang, 2017). Microparticles (MPs), which are small membrane vesicles released from activated 
cells, are being currently heavily investigated as promising biomarkers and vectors for multiple 
cerebrovascular disorders including stroke.  
The primary purpose of this review is to highlight the emerging role of MPs in cerebrovascular 
disease and specifically focusing on MPs of endothelial and platelets origins because they reflect, 
respectively, endothelial activation and thrombotic activity, two major contributors to the 
pathophysiology of ischemic stroke. We will initially review the current understanding of the 
roles of MPs and then focus on their importance in the understanding of cerebrovascular disease. 
Cell membrane remodeling and microparticles (MPs) release 
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Extracellular vesicles (EVs) are submicron, intact membrane-derived vesicles that are released 
from cells after activation or during apoptosis (Shet, 2008). These vesicles harbor membrane 
constituents such as phospholipids, integral membranes and receptors as well as cytoplasmic 
cargo including various proteins, DNA and RNA adopted from their cells of origin (Hargett & 
Bauer, 2013; Hugel, Martinez, Kunzelmann, & Freyssinet, 2005). There are several types of EVs 
characterized based on their size and formation/release pathways including, MPs, exosomes, 
oncosomes and apoptotic bodies (Zaborowski, Balaj, Breakefield, & Lai, 2015). MPs were first 
discovered in 1967 by Wolf during his ongoing coagulation studies when he observed 
subcellular coagulant vesicles in platelet-free plasma to which he referred to as “platelet dust” 
(Wolf, 1967). Subsequently, numerous studies have been conducted to further investigate the 
structure, biogenesis and functions of these vesicles gradually replacing it by the term MPs 
(Crawford, 1971; Hargett & Bauer, 2013; Webber & Johnson, 1970). Over the past 40 years, the 
understanding of MPs has tremendously advanced from being viewed as useless cell debris or 
cellular trash to one of the key cellular players regulating various physiological and pathological 
processes throughout the body (Hargett & Bauer, 2013). In 2005, a standard definition for MPs 
has been proposed by The International and Haemostasis Vascular Biology subcommittee. They 
described MPs as 0.1-1 micrometer cell-derived vesicles that lack a nucleus or synthetic 
capacity, may contain cytoskeletal proteins, and expose some quantity of phosphatidylserine on 
their surfaces (Hargett & Bauer, 2013). 
Mechanisms of MP formation and shedding 
The shedding of MPs from plasma membrane is an essential part of cell membrane remodeling 
and is thought to be initiated by increased intracellular calcium (Shet, 2008). The phospholipid 
cell membrane bilayer is well-structured and each of the two leaflets has a specific lipid 
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composition. Phospahtidylcholine and sphingomyelin are expressed on the outer leaflet while 
aminophospholipids [Phosphatidylserine (PS) and phosphatidylethanolamine] are oriented 
inwards (Hugel et al., 2005). Membrane enzymes; floppase, scramblase and aminophospholipid 
translocase (flippase) regulate phospholipid movements and maintain this dynamic asymmetry in 
a steady state. Upon cell stimulation, cytosolic calcium increases which in turn dysregulates 
membrane enzymatic balance and leads to the collapse of membrane asymmetry and subsequent 
externalization of PS. In addition, intracellular calcium activates calpain and Rho kinase which 
together cause cytoskeleton cleavage and rearrangement facilitating thus membrane blebbing as 
well as activating apoptosis via a caspase 3-mediated pathway. However, it must be noted that 
other stimuli that cause disruption of membrane integrity can also lead to the formation of MP 
(Hugel et al., 2005). Moreover, it has been shown that MPs can be released from inactivated 
platelets without intracellular calcium signaling and it was observed that this mechanism was 
dependent on αIIβ3 integrin and cytoskeleton turnover (Cauwenberghs et al., 2006). Therefore, 
other pathways are also most probably involved in the formation of MPs hence adding to the 
complexity of the biology of MP formation and release. Further research is required to fully 
elucidate the mechanisms governing the formation and shedding of MPs from cell membranes.  
Properties and characteristics of MPs 
MPs have been found to be present in blood stream of healthy individuals as well as in patients 
(Berckmans et al., 2001; Martinez, Tesse, Zobairi, & Andriantsitohaina, 2005). This suggests 
that MPs can be beneficial; maintaining homeostasis under normal physiological conditions, or 
deleterious if overproduced or if they carry pathogenic constituents on their surface or in cargo 
(Hugel et al., 2005). The concept of MPs is interesting as they are considered a circulating 
storage pool of bioactive molecules that if interpreted correctly can provide valuable insight 
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about the body state and can be used as biomarkers for various pathological states (Hugel et al., 
2005). Additionally, MPs act as a form of effective intercellular communication system 
regulating various fundamental biological processes (Hoyer, Nickenig, & Werner, 2010). Studies 
have shown that MPs convey biological information by either direct interaction with cell 
receptors/integrins initiating cell signaling cascades or by direct fusion with effector cells by 
endocytosis and the subsequent emptying of MPs content (Hargett & Bauer, 2013). In this sense, 
MPs can act as a signaling molecules via the expression of different proteins and lipids on their 
surface such as tissue factor (TF) and PS (Hoyer et al., 2010). Alternatively, MPs have been 
shown to transfer complete receptor proteins (e.g., CCR5 receptor), mRNA, microRNAs, 
proteins and even cellular organelles to recipient cells (Deregibus et al., 2007; Hoyer et al., 2010; 
Mack et al., 2000; Ratajczak et al., 2006). Nevertheless, more studies are required to confirm that 
molecular material transferred to recipient cells are biologically functional and significantly 
affecting cellular responses in target cells (Zaborowski et al., 2015). MPs are very heterogeneous 
and vary widely depending on the stimulus and cell of origin. For example, the release of MPs in 
vitro can be induced using a plethora of agents and the resulting MPs vary in structure and 
composition (Herring, McMichael, & Smith, 2013). For instance, previous studies have shown 
that in vitro stimulation of human lymphoid CEM T cell line using two different 
pharmacological stimuli generated antigenically and functionally different MP populations. 
When the CEM cell line was stimulated with phytohemagglutinin for 72h, followed by phorbol-
12-myristate-13 and actinomycin D for further 24h, generated MPs  harbored the morphogen 
Sonic hedgehog (Shh) and were found to improve endothelial function both in vitro and in vivo 
(Agouni et al., 2007). However, when the same cell line was stimulated with an apoptotic signal 
using actinomycin D for 24h, MPs generated failed to express the morphogen Shh and caused a 
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deleterious effect on endothelial function both in vitro and in vivo (Mostefai et al., 2008). These 
studies highlight the importance of the stimulus at the origin of generating MPs in conditioning 
the antigenic content and biological messages carried out by the shed extracellular vesicles.  
Functions of MPs  
MPs are involved in various vital biological functions such as hemostasis, coagulation, 
inflammation and angiogenesis (Herring et al., 2013). It has been shown that some MPs may 
have procoagulant activity due to the externalization of PS which acts as a catalytic surface for 
enzymatic coagulation complexes assembly (Mooberry & Key, 2016). In addition, some MPs 
harbor TF on their surface which is considered to be the main initiator of coagulation cascade in 
the extrinsic pathway (Meziani, Tesse, & Andriantsitohaina, 2008). Remarkably, one study 
showed that PMPs have 50 to 100 more procoagulant activity when compared to activated 
platelets (Sinauridze et al., 2007). Additionally, MPs have been shown to play a role in 
hemostasis disorders such as Scott Syndrome, hemophilia A and Von Willebrand disease (VWD) 
(Mooberry & Key, 2016). There is also evidence showing that MPs may have anticoagulant and 
fibrinolytic activity as well (Mooberry & Key, 2016). MPs have been shown to carry TF 
pathway inhibitor (TFPI) on their surface and to promote the activity of the anticoagulant protein 
C (Koshiar, Somajo, Norstrom, & Dahlback, 2014; Kushak et al., 2005; Steppich et al., 2005; 
Tans et al., 1991). Therefore, the role of MPs in regulating coagulation is complex and depends 
on the context of their release. Similarly, MPs are involved in inflammation by facilitating the 
interaction between immune cells, providing a source of aminophospholipids and participating in 
the release of cytokines (Meziani et al., 2008; Puddu, Puddu, Cravero, Muscari, & Muscari, 
2010). Furthermore, numerous studies have shown that MPs can regulate angiogenesis and 
modulate several steps in blood vessels’ formation  (Martinez & Andriantsitohaina, 2011). The 
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effects of MPs on the vascular system have been investigated intensively as well. Although it has 
been shown that some MPs have positive effects on endothelial function, many studies 
demonstrated that MPs can induce endothelial dysfunction (Agouni et al., 2007; Mostefai et al., 
2008). Some of the mechanisms by which MPs induce endothelial dysfunction include, reducing 
nitric oxide (NO) concentration, inducing inflammation, promoting coagulation, altering 
angiogenesis and apoptosis (Lovren & Verma, 2013). A cellular MP and its proposed functions 
on coagulation, angiogenesis, inflammation and vascular function are illustrated in Figure 1. 
Challenges with the analysis of MPs in clinical practice 
Given the importance of MPs as potential biomarkers of disease and vectors of biological 
messages, they have attracted attention from the scientific community; however, various 
challenges related to the methods of detection and analysis of MPs are hindering the wide 
application of MPs in clinical use. Such challenges include: 
1. Methods to isolate MPs are not fully developed and standardized yet. Most of the current 
isolation methods allow enrichment rather than separation of EV subtype populations 
(Zaborowski et al., 2015). Each of the methods available has its pitfalls and there is no 
standard protocol for MP isolation. For instance, series of ultra-centrifugations yields are 
means of good separation of EVs; however, it is often contaminated with high molecular 
weight protein complexes and cannot differentiate between EVs subtypes and cells of 
origin. Immunoaffinity-based assays provide better enrichment of EV-specific subtypes 
and provide more homogenous EV profiles but the overall yield is low. Many MPs 
subtypes share the same CD pattern of expression and therefore, combining multiple 
markers to exclude possible subpopulation contamination has been used to overcome this 
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issue. For example, Simak et al. (Simak, Gelderman, Yu, Wright, & Baird, 2006) used 
cell-specific antibodies combinations to ensure the detection of endothelial MPs while 
making sure to eliminate MPs of platelet, leukocyte or erythrocyte origins (Simak et al., 
2006).  
2. MP quantification is highly challenging. Maas et al. (Maas et al., 2015) conducted a 
thorough comparison between three of the most common methods used to quantify MPs 
namely; nanoparticle tracking analysis (NTA), tunable resistive pulse sensing (tRPS) and 
flow cytometry and found substantial differences in EVs counts among these techniques. 
The study also reiterated the importance of proper technical knowledge of the instruments 
and their settings and its effect on correct data interpretation (Maas et al., 2015).  
3. Handling and processing of blood samples is very crucial and may introduce variability 
when comparing different studies. Aspects of sample collection, including needle size, 
the use of tourniquet, the use of syringe versus vacutainer and the type of anticoagulant 
used. In addition, special attention should be given to speeds of centrifugation, number of 
centrifugations, freeze/thaw cycles and the duration of MPs storage (Shet, 2008). 
4. Proper identification of MPs is also very challenging.  Arraud et al. (Arraud et al., 2014) 
conducted an interesting study to examine MPs morphology and size in which they found 
that MPs (which were mainly of platelet and erythrocyte origins) are spherical and 
tubular in shape. Although tubular MPs constituted a small percentage, the total 
membrane surface area was of the same order of magnitude as spherical MPs. In addition, 
they found that the majority of MPs in their study did not bind Annexin V which is in 
contrast with the theory that MPs expose PS when they are formed. They have concluded 
that these MPs might be formed via a mechanism that maintain the membrane 
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phospholipid asymmetry such as direct cell fragmentation or breakdown from PS 
negative tubular MPs (Arraud et al., 2014).  
Since not all studies take these challenges into account, especially older ones, it is very hard to 
compare and analyze findings reported from various studies. 
MPs and stroke 
Almost all cell types are capable of producing and shedding MPs (Shet, 2008). Circulating MPs 
have been shown to be released from platelets, erythrocytes, leukocytes, endothelial cells and 
smooth muscle cells (Chiva-Blanch et al., 2016). Numerous studies reported elevated levels of 
MPs in cardiovascular diseases and ischemic disorders (Agouni, Andriantsitohaina, & Martinez, 
2014). MPs have been linked to multiple pathological states including, atherosclerosis, diabetes, 
myocardial infarction, metabolic syndrome, hypertension, cancer, preeclampsia and sepsis 
(Herring et al., 2013; Lovren & Verma, 2013; Meziani et al., 2008). 
Several studies are now being conducted to investigate the potential role of MPs in the context of 
stroke. It was recently reported in a systematic review that circulating MPs from various cell 
origins increase in ischemic stroke patients (Wang et al., 2018). Since endothelial dysfunction 
and thrombotic dysregulation are two major contributors to the pathophysiology of stroke, in this 
review we focused on the role of endothelial-derived MPs (EMPs), as key biomarkers of 
endothelial activation and dysfunction, and platelet-derived MPs (PMPs), as biomarkers of 
thrombotic state, in the development of stroke. We also reviewed their value as biomarkers in the 
onset and progression of the disease. Surface antigens that characterize EMPs and PMPs and 
their functions are summarized in Table 1.  
Endothelial-derived MPs (EMPs) and stroke 
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Endothelial dysfunction is evident early and is recognized as an important initiator of 
cerebrovascular disease (Lovren & Verma, 2013). MPs shed from endothelial cells are involved 
in inflammation, pro-coagulation and angiogenesis and thus are considered as a biomarkers of 
endothelial cell activation and injury (Martinez et al., 2005). Profiling of EMPs in stroke may 
provide understanding of the pathogenesis of the disease and reflect its prognosis. Distinct 
endothelial MPs phenotypes are released depending on the type of stimulus the cells are 
subjected to. When endothelial cells were activated by tumor necrosis factor (TNF)-α in vitro, 
CD62E+ (E-selectin) MPs were released. E-selectin participate in leukocyte and platelet 
recruitment and therefore its release is a marker of ongoing inflammation and endothelial 
activation. On the other hand, apoptotic endothelial cells shed MPs with specific markers such as 
CD31+  (PECAM-1) and thus used as a marker for apoptosis (Jimenez et al., 2003). EMPs 
released from activated cells are CD62E+ (E-selectin), CD54+ (ICAM-1) and CD106+ (VCAM-
1), whereas EMPs released upon apoptosis include CD31+ (PECAM-1), CD105+ (endoglin), 
CD146+ (MCAM) and CD144+ (VE-cadherin) (Deng, Wang, & Zhang, 2017). Despite 
differences in settings between the different studies reported, some conclusions can be drawn.  
CD62E+ (E-selectin) has been measured in several stroke studies (Chiva-Blanch et al., 2016; 
Jung et al., 2009; Lackner et al., 2010; Lee et al., 2012; P. Li & Qin, 2015; Williams, Jauch, 
Lindsell, & Campos, 2007). It has been shown that CD62E+  EMPs are increased in ischemic 
stroke patients when compared to healthy controls and remained high when assessed after 7 and 
90 days (Chiva-Blanch et al., 2016). High levels of CD62E+ EMPs have also been associated 
with recent ischemic attacks and increased risk of cardiovascular events; however, no association 
has been found between CD62E+ EMPs and stroke onset or recurrence (Chiva-Blanch et al., 
2016; Jung et al., 2009; Lee et al., 2012). Since E-selectin is a member of the adhesion molecule 
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family that facilitates inflammatory cells’ adhesion and rolling, these findings suggest the 
following hypotheses. First, high levels of CD62E+ EMPs without being correlated to the time of 
stroke onset demonstrate continuous endothelial cell activation. Second, endothelial dysfunction 
in ischemic stroke is more likely to be due to cell activation rather than apoptosis. Finally, the 
lack of correlation between CD62E+ EMPs and stroke recurrence while its association with 
cardiovascular events and hospitalization may suggest general endothelial dysfunction rather 
than pathology of cerebral ischemic origin (Chiva-Blanch et al., 2016; Jung et al., 2009; Lee et 
al., 2012).  
There is some suggestion that changes in  EMPs may be used as a biomarker of stroke severity 
(Chiva-Blanch et al., 2016; Jung et al., 2009; P. Li & Qin, 2015; Simak et al., 2006). Higher 
levels of EMPs have been found in patients with moderate/severe stroke versus mild stroke 
patients. Stroke severity was assessed using NIHSS scores where a score greater than 5 defined 
moderate/severe stroke while scores less than 5 indicated mild stroke. Li et al. (P. Li & Qin, 
2015) have shown a positive correlation between CD144+ (VE-cadherin) EMPs and stroke 
severity (P. Li & Qin, 2015). Another study using the same scale found an increase in some 
EMPs (including CD144+) in moderate to severe patients compared to mild stroke patients 
(Simak et al., 2006). Therefore, CD144+ EMPs have the potential to be used to assess stroke 
severity but further evidence is needed to confirm these findings. Additionally, EMPs can also be 
used in stroke diagnosis and identification of its etiology and subtypes. Simak et al. (Simak et al., 
2006) have shown some correlation between EMPs counts (CD105+ and CD54+) and brain lesion 
which can be useful to identify the extent of brain damage (Simak et al., 2006). In addition, Li et 
al. (P. Li & Qin, 2015) showed mild correlation between CD62E+ EMPs and OCSP 
classification which categorizes stroke subtypes according to ischemic lesion location (P. Li & 
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Qin, 2015). Therefore, CD62E+ EMP values may predict stroke subtypes. Furthermore, the ratio 
of CD62E+/CD31+ (E-selectin/PECAM-1) EMPs has been shown to be able to distinguish 
between the cause of arterial stenosis and whether it is of intracranial or extracranial origin thus 
providing potential information about stroke etiology (Jung et al., 2009).  
EMPs may also be useful in prognosis in patients with subarachnoid hemorrhage (SAH). One 
study conducted on patients with hemorrhagic stroke caused by SAH showed elevated levels of 
EMPs positive for CD54+ (ICAM-1), CD62E+ (E-selectin) and CD106+ (VCAM-1). Severe SAH 
may be followed by complications including cerebral vasospasm (CVS) and cerebral infarction 
attributable to vasospasm (CIV). This study measured EMPs in patients with CVS and CIV and 
found that only CD105+ (endoglin) EMPs were upregulated. Since endoglin is considered to be a 
marker of apoptosis, this finding showed that apoptosis may be a cause of endothelial damage in 
the early onset of CVS following hemorrhagic strokes (Lackner et al., 2010). It is also worth 
noting that Simak et al. (Simak et al., 2006) have observed a correlation between CD144+ (VE-
cadherin) EMPs and hemorrhagic transformation that occurred in 5 stroke patients during the 
study identifying it as a potential marker of acute intracerebral hemorrhage (Simak et al., 2006). 
Further studies are warranted to prove this correlation.  
Williams et al. (Williams et al., 2007) conducted a study to evaluate the effectiveness of EMPs 
as biomarkers to differentiate between stroke patients and stroke mimics (Williams et al., 2007). 
They measured CD62E+ (E-selectin) EMPs as a marker of endothelial activation and CD31+ 
(PECAM) EMPs as a marker of apoptosis in both groups. The ratio of CD62E+/CD31+ (E-
selectin/PECAM) EMPs was more than 4 in both groups indicating endothelial injury. However, 
the study showed no difference in EMPs count between stroke and mimic groups questioning the 
reliability of using EMPs as a marker to discriminate between them. There were some limitations 
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in this study including the low NIHSS score (small infarct volume) in stroke patients and the 
long sample storage time that may have affected the number of EMPs resulting in the 
underestimation of MP counts (Williams et al., 2007). Further studies may be required to 
confirm these findings and judge the effectiveness of EMPs as biomarkers in distinguishing 
between acute stroke and its mimics.  
In conclusion, EMPs evaluation studies conducted on stroke patients present a number of 
potential benefits in clinical settings but require further research. EMPs may potentially be used 
as biomarkers, provide insights about stroke severity and infarct lesion, differentiate between 
stroke subtypes and identify etiologies thereby, helping clinicians to make more effective 
therapeutic decisions. The ability to differentiate between stroke and mimics may also be very 
useful. 
Platelet-derived MPs (PMPs) and stroke 
PMPs are the most abundant MPs circulating in blood (Italiano, Mairuhu, & Flaumenhaft, 2010). 
Collection of PMPs requires careful processing because all platelets may not be successfully 
depleted from samples prior to measuring and thus may cause misinterpretation (Burnouf, 
Goubran, Chou, Devos, & Radosevic, 2014). This may be addressed by adding more 
centrifugation cycles which can decrease the content of platelets to up to 0.02%. PMPs are 
measured by many ways including physical methods such as flow cytometry and dynamic light 
scattering (Lawrie, Albanyan, Cardigan, Mackie, & Harrison, 2009; Shantsila, Montoro-Garcia, 
Gallego, & Lip, 2014). Other methods include assays that measure PMPs’ procoagulant activity, 
ELISA assays and proteomics (Burnouf et al., 2014; Capriotti et al., 2013; Osumi et al., 2001). In 
addition, cellular assays are conducted in vitro to measure the functional impact of PMPs on cell 
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proliferation, angiogenesis, inflammation and the release of cytokines (Burnouf et al., 2014). 
Flow cytometry and ELISA are the most commonly used methods to determine levels of PMPs 
in clinical trials.  
PMPs carry the surface antigens CD41+ (αIIb chain) and CD61+ (β3 integrin) which bind 
together to form GPIIa/IIb (integrin αIIbβ3) glycoprotein, CD 42a+ (GP IX) and CD 42b+ (GP1bα) 
which bind together to form (GP)Ib-IX-V complex and CD62P+ (P-selectin). Since 
atherosclerosis and thrombosis of cranial arteries are amongst the main causes of arterial 
occlusion and cerebral infarction, studies explored the role of platelets and its activation in stroke 
(Bivard, Lincz, Maquire, Parsons, & Levi, 2017; Chen et al., 2015; Chiva-Blanch et al., 2016; 
Kuriyama et al., 2010; Lackner et al., 2010).  
There are conflicting reports on PMPs following acute stroke or response to treatment. This may 
be attributed to differences in methods of detection. For instance, studies have shown elevated 
PMPs levels after acute ischemic stroke that remain elevated after antiplatelet therapy. Other 
studies showed a significant decrease in PMPs following the initiation of antiplatelet medications 
(Chen et al., 2015; Chiva-Blanch et al., 2016; Kuriyama et al., 2010; Shirafuji, Hamaguchi, & 
Kanda, 2008). Similarly, some studies associated elevated PMPs with the acute phase of cerebral 
infarction while others linked it to the chronic phase (Kuriyama et al., 2010; Shirafuji et al., 
2008). Nevertheless, most of the studies showed that there are higher levels of PMPs post-stroke 
(ischemic and hemorrhagic) which means that PMPs can be used as biomarkers for diagnosis; 
however, the benefits of measuring PMPs levels for assessing clinical outcomes after antiplatelet 
therapy remain to be elucidated (Chen et al., 2015; Chiva-Blanch et al., 2016; Kuriyama et al., 
2010; Lackner et al., 2010; Pawelczyk, Baj, Chmielewski, Kaczorowska, & Klimek, 2009; 
Shirafuji et al., 2008). Measuring PMPs showed a potential benefit in identifying stroke etiology. 
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Studies have shown higher levels of PMPs in patients with large artery arteriosclerosis (LAA) 
and small artery occlusion (SAO) when compared to controls, patients with cardioembolic 
thrombi and other unidentified etiologies (Chen et al., 2015; Kuriyama et al., 2010). In addition, 
Chiva-blanch et al. (Chiva-Blanch et al., 2016) showed that there are higher CD62P+ (P-selectin) 
PMPs in LAA subtype compared to other stroke etiologies at 90 days but not at onset of stroke 
(Chiva-Blanch et al., 2016). Furthermore, PMP levels were higher in patients with stenotic 
lesions of intracranial arteries and thickness of intima media (Kuriyama et al., 2010).  
PMPs may be markers of successful treatment following an acute stroke. PMP levels were  
related to better reperfusion and recanalization outcomes in acute ischemic stroke patients 
receiving recombinant tissue plasminogen activator (rt-PA) making it a potential candidate to 
assess recanalization in stroke patients (Bivard et al., 2017). However, it was noted that PMP 
levels were not related to infarct size and only a weak correlation has been observed between 
PMP levels and infarct volume in LAA subtype (Chen et al., 2015; Kuriyama et al., 2010). 
Taken together, PMPs appear to be good biomarkers for stroke diagnosis and determining stroke 
etiology but subsequent measuring for follow-up purposes needs more standardization for a 
better identification of the value of PMPs as biomarkers for stroke recurrence and prognosis. 
PMPs may also be of potential value in determining reperfusion in patients being treated with rt-
PA. 
Clinical utility of MPs in stroke 
Since MPs play pivotal role in the pathophysiology of different diseases, its clinical applications 
have been widely investigated. One of the approaches is to use MPs to evaluate and monitor 
therapeutic efficacy (Chen, Li, & Liu, 2018). For example, some drugs such as statins, aspirin 
and anti-oxidants have been shown to reduce MPs levels in patients and thus can be used to 
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assess treatment effectiveness (Baron, Boulanger, Staels, & Tailleux, 2012; Bulut, Becker, & 
Mugge, 2011; Morel et al., 2003; Suades, Padro, Alonso, Mata, & Badimon, 2013). Another 
approach is utilizing MPs characteristics as therapeutic agents. For instance, the ability of some 
MPs to stimulate the formation of new blood vessels has been shown to induce revascularization 
and improve mouse kidney function in an ischemia/reperfusion injury model (Ranghino et al., 
2012). In addition, as stated earlier, MPs carry genetic material cargo such as DNA, mRNA and 
microRNA which can be transferred to distal cells (Hugel et al., 2005). Therefore, MPs have the 
potential to be used in gene therapy or as non-toxic therapeutic delivery tools (Chen et al., 2018). 
MPs provide the advantage of being non-toxic and stable in blood; however, the effectiveness of 
the genetic material or drug delivery to target cells is still to be elucidated (Chen et al., 2018). 
Furthermore, due to MPs coagulant activity especially of platelet-derived MPs, their use as 
prothrombotic agents has been explored to treat bleeding disorders like thrombocytopenia 
(Blajchman, 2003; Piccin, Murphy, & Smith, 2007). Therefore, various functions of MPs could 
be utilized to provide therapeutic effects. Also, one of the main promising clinical applications of 
MPs is their use as biomarkers and diagnostic tools. As mentioned earlier, MPs levels vary with 
many diseases and therefore could be used for diagnosis (Hugel et al., 2005). Researchers tried to 
investigate changes in circulating MPs patterns of expression that can be distinctive to certain 
phenotypes of disease (A. Berezin, 2016). For example, studies by Berezin et al. have widely 
investigated the imbalance between MPs released from apoptotic versus activated endothelial 
cells, to which has been referred to as “impaired phenotype”, to provide predictive scores for 
heart failure assessment and predicting cardiovascular risks (A. Berezin, 2016; A. E. Berezin, 
Kremzer, Martovitskaya, Samura, & Berezina, 2015; A. E. Berezin, Kremzer, Samura, Berezina, 
& Kruzliak, 2015). These scores have been shown to provide better predictive values when 
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combined with other markers in heart failure patients (A. E. Berezin, Kremzer, Martovitskaya, 
Berezina, & Samura, 2015). A similar score has also been used for stroke diagnosis where a ratio 
between CD62E/CD31 has been used rather than absolute numbers to discriminate between 
endothelial activation and apoptosis and to identify the site of arterial stenosis (Jimenez et al., 
2003; Jung et al., 2009). In the context of stroke, the use of MPs as diagnostic tools could 
provide potential value given challenges in stroke’s diagnosis. Imaging equipments are 
expensive, not easily available, time consuming and require professional interpretation (Saenger 
& Christenson, 2010). Thus, there is a need for novel stroke biomarkers characterized by early 
and steady release after infarction, improved sensitivity and specificity over current biomarkers 
that could differentiate between stroke types and stroke mimics (Saenger & Christenson, 2010). 
MPs are being investigated as a promising candidate, but their use is faced by some challenges 
with regards to sample handling and reliable measurement tools as discussed earlier in this 
review. Nevertheless, as referred in Figure 2, promising fields include the use of MPs to predict 
severity of infarct, site of injury and differentiate between different phenotypes. In addition, MPs 
can also be used to monitor therapeutic efficacy and predict survival rates as shown by Bivard et 
al. (Bivard et al., 2017) relating PMPs with better recanalization outcomes (Bivard et al., 2017). 
More studies are warranted to confirm MPs value in stroke treatment and diagnosis.  
Conclusions  
Normal basal levels of MPs reflect a tightly controlled balance between cell survival, 
proliferation and death. Based on the nature of the stimulus that causes their release, this balance 
is shifted to either direction with changes in the levels and composition of MPs and upon which 
MPs could be good or bad. Given the complexity of MPs functions and roles, it is still a matter 
of debate whether they are a cause or a consequence, friends or foes, active participants or 
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passive observers. Nevertheless, MPs acting as remarkable biological sensors are very attractive 
targets for studying and exploring novel and personalized therapeutic strategies. In this review, 
we reviewed in more detail the roles of EMPs and PMPs in stroke patients (studies are 
summarized in Table 2). Despite the challenges, EMPs and PMPs could provide potential 
benefits as biomarkers, diagnostic tools and prediction of stroke severity (promising markers are 
illustrated in Figure 2). However, standardization of MPs detection and quantification methods 
is highly required to further confirm and generalize the results. 
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Table 1. List of EMP and PMP surface markers according to their cell origins and 
functions 
CD 
marker 
Antigen Function Refs 
Endothelial-derived MPs (EMPs) 
CD62E E-selectin 
 
Cell adhesion molecule induced in response to 
inflammation and is thought to play a role in 
recruiting leukocytes to the sites of injury 
(Deng et al., 
2017) 
CD105 Endoglin 
 
Part of TGF-β receptor complex. Largely 
expressed on endothelial cells and induced during 
angiogenesis and inflammation. 
(Fonsatti & 
Maio, 2004) 
CD144 VE-cadherin 
(Vascular 
endothelial 
cadherin) 
Constitutively expressed at endothelial adherence 
junctions. It plays a role in controlling vascular 
permeability and leukocyte extravasation. 
(Vestweber, 
2008) 
CD31 PECAM-1 
(Platelet and 
endothelial 
cell adhesion 
molecule) 
It is expressed in most vascular compartment cells. 
It is found at cell junctions in endothelial cells and 
play various roles in inflammation and vascular 
biology. 
(Woodfin, 
Voisin, & 
Nourshargh, 
2007) 
CD54 ICAM-1 
(Intercellular 
adhesion 
molecule) 
It is an inducible cell adhesion protein that plays a 
role in leukocyte and endothelium interaction to 
regulate vascular permeability. It is also induced in 
inflammation and is expressed on a wide range of 
immune cells such as monocytes and macrophages. 
(Roebuck & 
Finnegan, 
1999) 
CD146 MCAM 
(melanoma 
cell adhesion 
molecule) 
Adhesion molecule involved in cell signaling, 
vascular permeability and immune response. 
(Shih, 
1999) 
CD106 VCAM-1 
(vascular cell 
adhesion 
molecule) 
It is a transmembrane glycoprotein and is a marker 
of endothelial cell activation and induced in 
inflammation. 
(Ley & 
Huo, 2001) 
Platelet-derived MPs (EMPs) 
CD41 
CD61 
αIIb chain 
β3 integrin 
Bind together to form the glycoprotein GPIIa/IIb 
(integrin αIIbβ3) which is a member of the integrin 
transmembrane family. It is expressed on platelets 
and is essential for platelets aggregation. It acts as 
a receptor for fibrinogen and vonWillebrand factor 
(vWF) to facilitate platelets aggregation and cross 
linking. 
(Fullard, 
2004) 
CD42a 
CD42b 
GP IX 
GP1bα 
 
Two membrane glycoproteins that bind together to 
form (GP)Ib-IX-V complex. (GP)Ib-IX-V is 
expressed on platelets surface and is involved in 
thrombosis and acts as a receptor for vWF and 
(R. Li & 
Emsley, 
2013) 
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other molecules such as thrombin. 
CD62P P-selectin Also known as Platelet Activation-Dependent 
Granule to External Membrane Protein 
(PADGEM) or Granule Membrane Protein 140 
(GMP-140). It is a transmembrane glycoprotein 
that is expressed by activated platelets and plays a 
key role in immune cells adhesion and rolling. 
 
(Koedam et 
al., 1992) 
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Table 1. Summary of key studies that investigated EMPs and PMPs in stroke patients 
Type of stroke Time of sample 
collection 
MP marker Findings Strengths and 
weaknesses 
Refs 
 
Endothelial-derived MPs (EMPs) 
 
Patients with acute 
cerebral ischemia 
divided into two 
groups according to 
NIHSS scores: 
 
1. Mild stroke; 
score <5 
2. Moderate to 
severe stroke; 
score ≥5 
 
Median time of 
37 h (18.5 -
51.8) after onset 
of clinical 
symptoms 
• Endoglin 
CD105+CD41a-
CD45- (E+EMP) 
• VE-cadherin and 
endoglin: 
CD105+CD144+ 
(C+EMP) 
• Phosphatidyl 
Serine: 
CD105+PS+CD41a-
(PS+EMP) 
• ICAM-1: 
CD105+CD54+CD
45- (I+EMP) 
• PS+EMP were 
significantly higher 
in all stroke groups 
compared to 
controls, other 
phenotypes 
increased but not 
significantly 
(marker of 
procoagulant 
endothelium) 
• C+EMP and I+EMP 
levels were also 
significantly higher 
in the moderate to 
severe group 
relative to the mild 
stroke group 
subjects (marker 
of stroke severity) 
• Significant 
correlation 
between I+EMP 
(ICAM-1) count 
and brain lesion 
was observed, less 
Strengths: 
• The use of 
multiple EMP 
antigens to avoid 
contamination 
with MPs of 
other origins 
• Measuring 
markers of 
apoptosis and 
activation 
 
Weaknesses: 
• No test has been 
made to relate 
the increase of 
PS+EMP with 
other 
prothrombotic 
markers to prove 
its role in 
procoagulation 
(Simak et al., 
2006) 
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correlation with 
PS+EMP, E+EMP. 
(marker for 
degree of 
inflammation and 
apoptosis within 
ischemic lesion)  
• Possible 
association 
between C+EMP 
and hemorrhagic 
transformation 
(diagnosis of 
intracerebral 
hemorrhage) 
 
Patients suspected 
with ischemic 
stroke vs controls at 
high risk of 
cardiovascular 
disease  
• Within 48 h 
after onset 
of stroke 
 
• Then after 7 
and 90 days 
• MCAM: CD146+ 
• E-Selectin:CD62E+ 
• Higher EMPs 
counts in ischemic 
stroke patients 
compared to 
controls that have 
been sustained 
after 7 and 90 days 
with EMP showing 
the most increase 
compared to others 
(approximately 
300-fold increase) 
(biomarker and 
diagnosis) 
• No correlation 
between CD62E+ 
and the time of 
Strengths: 
• Measuring 
markers of 
apoptosis and 
activation 
 
Weaknesses: 
• More measures 
should be taken 
to eliminate 
interference of 
MPs of other 
origins 
• Only PS+ MPs 
have been 
measured 
(Chiva-
Blanch et al., 
2016) 
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stroke onset 
(continuous cell 
activation) 
• CD62E+ (marker 
of activation) more 
than CD146+ 
(marker of 
apoptosis) 
(evidence of 
selective 
packaging of 
MPs) 
• No correlation with 
lesion volume 
Patients with acute 
ischemic stroke 
(AIS) vs age- and 
sex-matched 
healthy controls 
 
Stroke patients 
divided into: 
 
1. Mild stroke; 
score <5 
2. Moderate to 
severe stroke; 
score ≥5 
 
 
Within 7 days 
of the onset of 
clinical 
symptoms 
• VE-cadherin: 
CD144+/CD41a- 
• PECAM-1: 
CD31+CD41a-  
• E-Selectin CD62E+ 
• E-Selectin PS: 
AV+CD62E+ 
• All EMPs 
increased in all 
acute stroke 
patients compared 
to controls. All 
EMPs were 
increased in mild 
stroke compared to 
controls. Only 
EMPs have 
increased in 
moderate to severe 
stroke patients 
compared to 
controls 
(biomarker) 
• Levels of 
CD144+/CD41a- 
(VE-cadherin) 
Strengths: 
• Measuring 
markers of 
apoptosis and 
activation 
• Correlation with 
stroke subtypes 
 
Weaknesses: 
• Small-sized MPs 
may have not 
been captured, 
hence 
underestimating 
the count. 
(P. Li & Qin, 
2015) 
 35 
microparticles 
were significantly 
correlated with 
stroke severity 
based on NIHSS 
scores (stroke 
severity). 
• A mild degree of 
correlation was 
evident between 
AV+ CD62E+ 
microparticles and 
stroke subtype 
based on OCPS 
classification 
(identification of 
stroke subtype). 
Acute stroke 
patients vs patients 
with vascular risk 
factors but no 
stroke events 
Within 7 days 
of stroke 
symptoms onset 
• PECAM-1: 
CD31+/CD42b- 
• AV+PECAM: 
CD31+/AV+ 
• E-Selectin: CD62E+ 
• Higher levels of 
CD62E+ were 
associated with 
recent ischemic 
attack and 
moderate to severe 
stroke (biomarker 
and severity). 
• The ratio of 
CD62E+ to 
CD31+/CD42b- or 
CD31+/AV+ EMP 
levels significantly 
discriminated 
extracranial and 
intracranial arterial 
Strengths: 
• Measuring 
markers of 
apoptosis and 
activation 
• Correlation with 
stroke etiology 
 
Weaknesses: 
• No follow-ups 
have been 
performed 
 
 
 
 
(Jung et al., 
2009) 
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stenosis (stroke 
etiology). 
 
Patients with stroke 
history at least 3 
months prior to 
enrollment and 
compared to 
controls 
 
Patients divided 
into: 
 
1. Low CD62E+ 
MPs group 
2. High CD62E+ 
MPs group 
 
 
 
 
At least 3 
months before 
enrollment and 
followed-up 
every 3 to 6 
months for a 
total period of 
36 months 
• PECAM-1: 
CD31+/CD42- 
• AV+PECAM: 
CD31+/AV+ 
• E-Selectin: CD62E+ 
• A high level of 
CD62E+ MPs is 
associated with 
cardiovascular 
events in patients 
with stroke history 
(prognosis and 
identifying high 
risk patients) but 
not associated with 
stroke recurrence. 
• No association 
between 
CD31+/AV+ and 
cardiovascular 
events. 
Strengths: 
• Measuring 
markers of 
apoptosis and 
activation 
 
Weaknesses: 
• Heterogeneous 
patient 
population 
(including all 
types of stroke) 
• Few outcome 
events measured 
(Lee et al., 
2012) 
Acute ischemic 
stroke (AIS) 
patients vs mimics 
Samples were 
collected within 
24 h of 
symptoms onset 
and stored for 1-
2 years 
(prospective 
blood banking 
project)  
• PECAM-1:CD31+ 
• E-selectin: CD62E+ 
 
• EMP levels were 
similar in patients 
with AIS and 
stroke mimic 
patients.  
• The 
CD62E+/CD31+ 
ratio was more 
than 4 signifying 
that EMPs were 
generated via 
activation and not 
apoptosis/necrosis. 
Strengths: 
• Measuring 
markers of 
apoptosis and 
activation 
 
Weaknesses: 
• All types of 
stroke patients 
were included 
• Stroke patients 
had low NIHSS 
score which 
(Williams et 
al., 2007) 
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(This suggests 
that EMPs may 
not be a good 
marker for AIS, 
given the lack of 
ability to 
distinguish 
between stroke 
and its mimics) 
means smaller 
infarct lesions 
therefore, it 
might have 
caused 
underestimation 
of EMPs 
released 
• Patient samples 
were stored for 
1.5 years at -
70°C and 
subjected to one 
freeze/thaw 
cycle which also 
might affect 
EMPs count 
Hemorrhagic stroke 
(subarachnoid 
hemorrhage SAH) 
vs healthy controls 
 
 
Within 48 h of 
stroke onset 
 
• Endoglin: CD105+ 
• VCAM-1: CD106+ 
• ICAM-1:CD54+ 
• E-Selectin:CD62E+ 
• Increased CD54+ 
(I-CAM), CD62E+ 
(E-selectin) and 
CD106+ (VCAM-
1) in SAH 
compared to 
controls (markers 
of endothelial 
activation) 
• Increased CD105+ 
at early cerebral 
vasospasm (CVS) 
especially those 
with cerebral 
infarction 
attributable to 
Strengths: 
• Exploring EMPs 
in hemorrhagic 
stroke 
 
Weaknesses: 
• Low number of 
patients (n=20) 
(Lackner et 
al., 2010) 
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vasospasm (CIV) 
(reflects apoptotic 
injury) 
 
Platelet-derived MPs (PMPs) 
Acute ischemic 
stroke (AIS) 
compared to controls 
 
AIS patients divided 
based on TOAST 
classification into: 
 
1. Large artery 
atherosclerosis 
subtype (LAA) 
2. Small artery 
occlusion (SAO)  
 
• After 48 h 
of stroke 
onset 
 
• And after 4-
weeks of 
antiplatelet 
therapy 
 
 
• β3 integrin: CD61+ • Basal levels of 
PMPs were higher 
in LAA and SAO 
subtypes compared 
to controls 
(biomarker) 
• No significant 
difference in PMP 
levels between 
LAA and SAO 
subtypes 
• PMP levels 
decreased in both 
subtypes after anti 
platelet therapy 
(prognosis and 
evaluation of drug 
response) 
• Weak correlation 
between PMP 
levels and infarct 
volume in LAA 
subtype. 
• PMPs could be 
independent risk 
factor for AIS 
patients. 
Strengths: 
• Measuring other 
platelet 
parameters 
along with 
PMPs. 
 
Weaknesses: 
• Using only one 
marker for 
detecting PMPs 
(CD61) 
 
(Chen et al., 
2015) 
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Acute ischemic 
stroke (AIS) patients 
receiving 
recombinant tissue 
plasminogen 
activator (rt-PA) 
therapy divided into: 
 
1. Patients with 
recanalization 
2. Patients without 
recanalization  
After 24 h of 
stroke onset 
• αIIb chain: CD41+ • CD41+ MPs were 
higher in patients 
with better 
recanalization 
outcomes  
• Total numbers of 
CD41+ related to 
reperfusion and 
recanalization as 
well as 3 months 
mRS. 
(assessing clinical 
outcomes) 
Strengths: 
• Following-up 
using mRS to 
assess 
outcomes 
 
Weaknesses: 
• Single time 
point 
measurement 
(at 24 h) which 
can be affected 
by many 
factors 
• No comparison 
with pre-
canalization 
levels  
(Bivard et 
al., 2017) 
Patients suspected 
with ischemic stroke 
vs controls at high 
risk of 
cardiovascular 
disease  
Within 48 h 
after onset of 
stroke 
 
And then after 7 
and 90 days 
• β3 integrin: 
CD61+/AV+ 
• β3integrin/TF: 
CD61+/CD142+/AV+ 
• P-selectin: 
CD62P+/AV+ 
• Higher levels of 
PMPs in patients at 
the onset of stroke 
compared to 
controls and 
maintained over 7 
and 90 days. 
• Higher 
CD62P+/AV+ and 
lower 
CD61+/CD142+/A
V+ 
in LAA subtype 
compared to other 
stroke etiologies 
Strengths: 
• Measuring 
markers of 
apoptosis and 
activation 
 
Weaknesses: 
• More measures 
should be taken 
to eliminate 
interference of 
MPs of other 
origins 
• Only PS+ MPs 
have been 
(Chiva-
Blanch et al., 
2016) 
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(based on TOAST 
classification) at 90 
days but not at 
onset of stroke. 
(etiology) 
measured 
Hemorrhagic stroke 
(subarachnoid 
hemorrhage SAH) vs 
healthy controls 
 
 
 
Within 48 h of 
stroke onset 
 
• αIIb chain:CD41+ 
• αIIb chain/ 
A+:CD41+/A+ 
• Mild increase in 
PMPs compared to 
controls 
(biomarker and 
diagnosis) 
Strengths: 
• Exploring EMPs 
in hemorrhagic 
stroke 
 
Weaknesses: 
• Small number of 
patients (n=20) 
(Lackner et 
al., 2010) 
Patients with acute 
phase cerebral 
infarction vs 
controls. Patients 
divided into: 
 
1. Small artery 
occlusion (S) 
2. Large artery 
atherosclerosis 
(L) 
3. Cardioembolism 
(CE) 
4. Stroke of 
undetermined 
etiology (U)  
Within 24 h of 
stroke onset 
 
After six 
months for 58 
patients with 
small vessel 
occlusion and 
large artery 
atherosclerosis 
• GbIb antibody 
(ELISA) 
• Elevated PMPs in 
S & L compared to 
control which 
means PMPs are 
higher in acute 
phase 
atherosclerotic 
cerebral infarction 
than in infarctions 
of cardiogenic 
origin. 
• PMPs were higher 
in patients with 
stenotic lesions of 
the intracranial 
arteries. 
• PMPs decreased 
after 6 months in S 
& L patients (more 
in acute than 
Strengths: 
• Correlating PMP 
levels with 
underlying 
causes and 
coagulation 
markers 
 
Weaknesses: 
• No follow-up to 
check the effect 
of decrease in 
PMPs on infarct 
size and final 
outcome 
 
  
(Kuriyama et 
al., 2010) 
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chronic phase) 
• No direct relation 
between PMPs and 
infarct size 
Patients with chronic 
phase of cerebral 
infarction (more than 
3 months) vs 
controls 
More than 3 
months from 
stroke onset 
• ELISA • Higher PMP levels 
in patients with 
chronic cerebral 
infarction that have 
remained elevated 
after antiplatelet 
therapy (4-week 
course) 
Strengths: 
• Comparing PMP 
levels before and 
after antiplatelet 
therapy 
 
Weaknesses: 
• Small number of 
patients 
 
(Shirafuji et 
al., 2008) 
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Figure Legends 
Figure 1. Structure and functions of MPs.  MPs are released from endothelial and platelet cells 
in resting state and upon stimulation. After membrane rearrangement, MPs externalize 
phosphatidylserine (PS) and harbor other cell surface molecules from their parent cells such as 
tissue factor (TF) and adhesion molecules (i.e. integrins, selectins and cadherins). In addition, 
they carry cargo including proteins, DNA, RNA, microRNAs and cytokines. Based on numerous 
factors, released MPs may play a role in various biological processes such as coagulation, 
angiogenesis, inflammation and vascular endothelium function regulation. The figure shows 
surface antigens expressed by EMPs and PMPs and the major biological processes they are 
involved in.  
Abbreviations: PECAM, Platelet and endothelial cell adhesion molecule; MCAM, melanoma 
cell adhesion molecule; VCAM-1, vascular cell adhesion molecule; ICAM-1, Intercellular 
adhesion molecule; VE-cadherin, vascular endothelial cadherin; GP, glycoprotein; MPs, 
microparticles. 
 
Figure 2. The most promising MP phenotypes for stroke diagnosis. 
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Figure 1. Structure and functions of MPs.  MPs are released from endothelial and platelet cells in resting state and upon stimulation. 
After membrane rearrangement, MPs externalize phosphatidylserine (PS) and harbor other cell surface molecules from their parent 
cells such as tissue factor (TF) and adhesion molecules (i.e. integrins, selectins and cadherins). In addition, they carry cargo including 
proteins, DNA, RNA, microRNAs and cytokines. Based on numerous factors, released MPs may play a role in various biological 
processes such as coagulation, angiogenesis, inflammation and vascular endothelium function regulation. The figure shows surface 
antigens expressed by EMPs and PMPs and the major biological processes they are involved in. Abbreviations: PECAM, Platelet and 
endothelial cell adhesion molecule; MCAM, melanoma cell adhesion molecule; VCAM-1, vascular cell adhesion molecule; ICAM-1, 
Intercellular adhesion molecule; VE-cadherin, vascular endothelial cadherin; GP, glycoprotein; MPs, microparticles.  
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